Clinical Results With the DNA Hypomethylating Agent 5-Aza-2'-Deoxycytidine (Decitabine) in Patients With Myelodysplastic Syndromes: An Update

Seminars in Hematology

Volumn 49, Issue 4, 2012, Pages 330-341

  Joeckel, Tina E ^a   Lübbert, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BUSULFAN; CARMUSTINE; ENTINOSTAT; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; LENALIDOMIDE; MELPHALAN; RETINOIC ACID; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOGENETICS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENGRAFTMENT; EPIGENETICS; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DNA METHYLATION; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TREATMENT OUTCOME;

EID: 84867606293     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.08.001     Document Type: Article

References (62)

1. Lübbert M., Miller C.W., Koeffler H.P. Changes of DNA methylation and chromatin structure in the human myeloperoxidase gene during myeloid differentiation. Blood 1991, 78:345-356.
2. Lugthart S., Figueroa M.E., Bindels E., et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 2011, 117:234-241.
3. Dacogen™ (decitabine) for injection US Food and Drug Administration, 1-16. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021790lbl.pdf.
4. Jones P.A., Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
5. Lübbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000, 249:135-164.
6. Pinto A., Zagonel V., Attadia V., et al. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989, 4(Suppl 3):28-32.
7. Zagonel V., Re Lo G., Marotta G., et al. 5-Aza-2'-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993, 7(Suppl 1):30-35.
8. Wijermans P.W., Lübbert M., Verhoef G., Klimek V., Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005, 84(Suppl 1):9-17.
9. Daskalakis M., Nguyen T.T., Nguyen C., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-2964.
10. Issa J.-P.J. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
11. Kantarjian H.M., Beran M., Ellis A., et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993, 81:1146-1151.
12. Kantarjian H.M., Cortes J., O'Brien S., et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002, 99:3547-3553.
13. Kantarjian H., Issa J.-P.J., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
14. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
15. Lübbert M., Suciu S., Baila L., et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011, 29:1987-1996.
16. Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
17. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
18. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
19. Kantarjian H.M., O'Brien S., Shan J., et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007, 109:265-273.
20. Berry D.A. Bayesian clinical trials. Nat Rev Drug Discov 2006, 5:27-36.
21. Kantarjian H.M., O'Brien S., Huang X., et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007, 109:1133-1137.
22. Steensma D.P., Baer M.R., Slack J.L., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the Alternative Dosing for Outpatient Treatment (ADOPT) trial. J Clin Oncol 2009, 27:3842-3848.
23. Steensma D.P. Decitabine treatment of patients with higher-risk myelodysplastic syndromes. Leuk Res 2009, 33(Suppl 2):S12-S17.
24. Iastrebner M., Jang J.H., Nucifora E., et al. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. Leuk Lymphoma 2010, 51:2250-2257.
25. Braun T., Itzykson R., Renneville A., et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011, 118:3824-3831.
26. Lee J.-H., Jang J.H., Park J., et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica 2011, 96:1441-1447.
27. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
28. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
29. Wijermans P., Krulder J., Huijgens P., Neve P. Continuous infusion of low-dose 5-aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997, 11:1-5.
30. Wijermans P., Lübbert M., Verhoef G., et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000, 18:956-962.
31. Reljic T., Bhansali N., Komrokji R.S., et al. Comparative effectiveness of azacitidene versus decitabine for the treatment of myelodysplastic syndromes. 52nd ASH Annual Meeting and Exposition 2010, poster session: Myelodysplastic Syndromes: Poster Board III-774 2010.
32. Kumar A., List A.F., Hozo I., Komrokji R., Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica 2009, 95:340-342.
33. Gurion R., Vidal L., Gafter-Gvili A., et al. 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome-A systematic review and meta-analysis. Haematologica 2010, 95:303-310.
34. Rüter B., Wijermans P.W., Lübbert M. Superiority of prolonged low-dose azanucleoside administration?. Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006, 106:1744-1750.
35. Borthakur G., Ahdab S.E., Ravandi F., et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008, 49:690-695.
36. Prebet T., Gore S.D., Esterni B., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
37. Fenaux P., Mufti G.J., Hellström-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
38. Fandy T.E., Herman J.G., Kerns P., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114:2764-2773.
39. Gore S.D., Baylin S., Sugar E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006, 66:6361-6369.
40. Itzykson R., Thépot S., Quesnel B., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117:403-411.
41. Möller I., Blum S., Gattermann N., et al. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Ann Hematol 2009, 88:1141-1144.
42. Fenaux P., Raza A., Mufti G.J., et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007, 109:4158-4163.
43. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with conventional care regimens in higher-risk myelodysplastic syndromes: results of a randomised, phase III study. Lancet Oncol 2009, 10:223-232.
44. Jabbour E., Kantarjian H., Kadia T., et al. Decitabine is effective in patients with myelodysplastic syndromes who failed prior intensive regimen: no negative impact of prior therapy. 52nd ASH Annual Meeting (poster) 2010.
45. Tees MT, Dolezal EK, Nimer SD, Klimek VM. Clinical activity of DNA methyltransferase inhibitors in therapy-related myelodyplastic syndromes: a retrospective study. 52nd ASH Annual Meeting and Exposition 2010, poster session: Myelodysplastic Syndromes: Poster Board I-871; 201AD.
46. De Padua Silva L., de Lima M., Kantarjian H., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009, 43:839-843.
47. Campo E., Swerdlow S.H., Harris N.L., et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
48. Lübbert M., Bertz H., Rüter B., et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009, 44:585-588.
49. Lübbert M., Rüter B., Claus R., et al. Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study. Blood 2007, 110(Suppl):300a.
50. Bertz H., Potthoff K., Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003, 21:1480-1484.
51. Appelbaum F.R., Rosenblum D., Arceci R.J., et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007, 109:1810-1816.
52. Marks R., Potthoff K., Hahn J., et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008, 112:415-425.
53. Cogle C.R., Imanirad I., Wiggins L.E., et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 2010, 8:40-46.
54. Kim D.-Y., Lee J.-H., Park Y.-H., et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome 2011, 47:374-379.
55. Scandura J.M., Roboz G.J., Moh M., et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011, 118:1472-1480.
56. Blum W., Klisovic R.B., Hackanson B., et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007, 25:3884-3891.
57. Kirschbaum M, Gojo I, Goldberg S, Kujawski L. Vorinostat in combination with Decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): A phase I, dose-escalation study. 51st ASH Annual Meeting And Exposition 2009, poster session: Acute Myeloid Leukemia: poster board II-66.
58. Uy GL, Abboud CN, Cashen AF, et al. Phase I study of panobinostat plus decitabine in elderly patients with advanced MDS or AML. 53rd ASH Annual Meeting and Exposition 2011, poster session: Acute Myeloid Leukemia: poster board I-40.
59. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
60. Lübbert M., Rüter B.H., Claus R., et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012, 97:393-401.
61. Sigalotti L., Altomonte M., Colizzi F., et al. 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood 2003, 101:4644-4646.
62. Almstedt M., Blagitko-Dorfs N., Duque-Afonso J., et al. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010, 34:899-905.